Rush University Medical Center

Rush Testing Remdesivir as a Potential Treatment for COVID-19

Up to 2,000 patients will be enrolled across all sites as part of an international study

Newswise — Rush University Medical Center is participating in a new clinical trial to test the effectiveness of the drug remdesivir in the treatment of coronavirus disease 2019 (COVID-19). This disease currently has no approved treatment.

Remdesivir is a novel antiviral drug that has shown promise in animal models for treating Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS1), which are caused by other coronaviruses. SARS-CoV-2, the virus that causes COVID-19, is an RNA (ribonucleic acid) virus, meaning RNA is its genetic material, unlike humans, in whom DNA (deoxyrib9onucleic acid ) forms the genetic material.

Remdesivir works by specifically targeting and disrupting the synthesis of RNA by inhibiting an enzyme called RNA polymerase. Studies have shown that this disruption can decrease viral replication.

“Currently, clinical decisions related to COVID-19 are based on the knowledge of how this drug worked during previous infectious disease outbreaks and safety trials, but we don’t know how effective it will be in treating COVID-19. This study aims to find that answer,” said Dr. Shivanjali Shankaran, infectious disease expert and principal investigator of the trial at Rush.

Remdesivir has been used in the past to treat other infections, such as Ebola. It also has activity against other coronaviruses that cause diseases, such as SARS and MERS.

Study will enroll patients with severe and moderate COVID-19

Outside of clinical trials, remdesivir only has been available to patients with COVID-19 under compassionate use – the use of unapproved drugs when no other treatment is available.

“This trial will help give us more robust data about effectiveness and side effects of this drug,” Shankaran said.

To qualify in the phase III randomized, trial, patients must be hospitalized with moderate to severe COVID-19 with lung abnormalities. Patients at Rush now are being given the option of enrolling in the study, which launched at Rush on April 3.

The study will include two groups of randomized patients with COVID-19; those with moderate or severe disease.

In the study, patients will receive either remdesivir or a nonactive substitute. This medication will be given intravenously for five to ten days. All patients also will receive supportive care (treatment of symptoms and side effects).

 “We will be looking at how long the patients are sick, if they had to be intubated and whether this treatment helps patients recover faster,” Shankaran said.

“Patients who agree to participate in this study will be followed closely during their hospitalization and up to a month after starting on the drug to evaluate how they are doing and how they are recovering. We will also evaluate for any side effects to the drug,” she added.

“Some side effects could include nausea, headaches, inflamed blood vessels or bruising. We will monitor patients for any additional side effects while they receive the medication.”

Rush is one of numerous worldwide sites of the study, which is sponsored by Gilead Sciences, Inc., a U.S. biotechnology company that developed remdesivir.

Rush University Medical Center has transformed its hospital to meet the increasing demand for care of patients with COVID-19. To date, the Medical Center and the other Rush University System for Health hospitals – Rush Copley Medical Center and Rush Oak Park Hospital – have 135 hospitalized COVID-19 patients, with many more expected.




Filters close

Showing results

110 of 5584
Released: 7-May-2021 1:40 PM EDT
There is no evidence that vaccines could cause harm to people who have recovered from COVID-19
Newswise

An article published by Robert F. Kennedy Jr.’s anti-vaccination organization and widely shared on social media questions the need of vaccinating those who’ve already recovered from COVID-19. The article says there’s a "potential risk of harm, including death" in getting the vaccines. We report this claim as false. There is no evidence that vaccinating people who had previously had COVID is resulting in an increased risk of adverse events.

Newswise: Abbott.jpg
Released: 7-May-2021 1:00 PM EDT
FSU expert available to discuss intellectual property and COVID-19 vaccines
Florida State University

By: Bill Wellock | Published: May 7, 2021 | 11:55 am | SHARE: President Joe Biden has expressed his support for a World Trade Organization proposal to waive intellectual property rights for COVID-19 vaccines.Florida State University law professor Frederick Abbott, the Edward Ball Eminent Scholar Professor of International Law, is available to comment on international intellectual property rights and global economic issues around the proposal.

access_time Embargo lifts in 2 days
Embargo will expire: 11-May-2021 11:00 AM EDT Released to reporters: 7-May-2021 1:00 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 11-May-2021 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 7-May-2021 11:15 AM EDT
Asthma attacks plummeted among Black and hispanic/latinx individuals during the COVID-19 pandemic
Brigham and Women’s Hospital

Asthma attacks account for almost 50 percent of the cost of asthma care which totals $80 billion each year in the United States

access_time Embargo lifts in 2 days
Embargo will expire: 11-May-2021 11:00 AM EDT Released to reporters: 7-May-2021 10:40 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 11-May-2021 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 7-May-2021 9:00 AM EDT
Navigating the COVID-19 crisis to prevent pressure injuries: Learning health system helped one hospital adapt and update care in real time
Wolters Kluwer Health: Lippincott

Early in the COVID-19 pandemic, healthcare systems scrambled to modify patient care processes – particularly when it came to strategies aimed at reducing the risk of hospital-related complications. A look at how one hospital applied its learning health system (LHS) framework to respond to a COVID-19-related increase in hospital-acquired pressure injuries (HAPIs) is presented in the May/June Journal for Healthcare Quality (JHQ), the peer-reviewed journal of the National Association for Healthcare Quality (NAHQ). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Newswise: Ultra-Fast COVID-19 Sensor Invented at Texas Tech Gets Boost Into International Markets
Released: 7-May-2021 8:55 AM EDT
Ultra-Fast COVID-19 Sensor Invented at Texas Tech Gets Boost Into International Markets
Texas Tech University

EviroTech LLC announced today (May 7) a $4 million investment into the company by 1701 Ventures GmbH of Göttingen, Germany, which will allow EviroTech to complete the final design, production startup and market introduction of its Ultra-Fast COVID-19 detection sensor.

Released: 7-May-2021 7:05 AM EDT
Rutgers Recruiting Participants for Pfizer COVID-19 Pediatric Vaccine Clinical Trial
Rutgers University-New Brunswick

Rutgers has been selected as a clinical trial site for the global Pfizer-BioNTech research study to evaluate the efficacy of its COVID-19 vaccine in children ages 6 months to 11 years. This is the third time Rutgers has served as a COVID-19 vaccine clinical trial site for pharmaceutical companies. Last fall, it conducted trials for Moderna and Johnson & Johnson.


Showing results

110 of 5584

close
1.83506